Radiation Boost Helps Cancer Survival
Posted on: Tuesday, 30 October 2007, 15:00 CDT
An extra radiation boost following breast cancer surgery and standard radiation helps prevent breast cancer return in young women, a Dutch study found.
Senior author Dr. Harry Bartelink, a radiation oncologist at The Netherlands Cancer Institute at Antoni van Leeuwenhoek Hospital in The Netherlands, said for patients with early stage breast cancer, the current standard treatment involves breast conserving surgery -- lumpectomy -- followed by radiation therapy to the breast over a 6- to 8-week period to kill any remaining cancer cells.
In this study, an additional boost of high-dose radiation was given after conventional radiation therapy to the lumpectomy site where the tumor was removed to potentially increase the chances of a cure, Bartelink said.
The study involved 5,318 women who underwent lumpectomies and whole breast radiation treatment as part of their breast conserving therapy for Stage I and Stage II breast cancer. The study subjects were evaluated 10 years after treatment and the largest benefits of the boost dose of radiation was in women under the age of 40, who have a higher risk to breast cancer recurrence to begin with, Bartelink said.
Bartelink presented the findings at the American Society for Therapeutic Radiology and Oncology's 49th annual meeting in Los Angeles.
Source: United Press International
Related Articles
- CuraGen Initiates Phase II Breast Cancer Study
- Genentech Reports Positive Results From Phase III Breast Cancer Study
- Novartis's Zometa Increases Survival Benefit in Phase III Breast Cancer Study
- WellStar Kennestone Hospital First Medical Center to Treat Early Stage Breast Cancer With New Treatment
- Bionovo's Publication Tagged As 'Critical Trial' By Leading Journal: Breast Cancer Research and Treatment
- No link between statins and breast cancer: study
- Novartis Submits Applications in U.S. And Europe for Femara As Adjuvant Treatment for Postmenopausal Women With Early Breast Cancer
- New Breast, Cervical Cancer Treatment Program Comes to Oklahoma
- Point Therapeutics Achieves Interim Tumor Response Criteria in Phase 2 Non-Small Cell Lung Cancer Study; Company Advances Talabostat to Second Stage of Study
- Breast Cancer Study Targets Sisters of Afflicted Women
User Comments (0)

RSS Feeds